Who are standard IV treatment for headache's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sumatriptan+Promethazine (SPr), ALMOTRIPTAN MALATE, Sumatriptan and Naproxen sodium, Imitrex®, conventional migraine drug treatment, Sumatriptan Succinate Oral Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-iv-treatment-for-headache.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

standard IV treatment for headache — Competitive Intelligence Brief

standard IV treatment for headache (standard IV treatment for headache) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triptan. Area: Neurology.

phase 3 Triptan 5-HT1B, 5-HT1D Neurology Small molecule Live · refreshed every 30 min

Target snapshot

standard IV treatment for headache (standard IV treatment for headache) — HCA Florida North Florida Hospital. Sumatriptan works by binding to serotonin receptors, specifically 5-HT1B and 5-HT1D receptors, to induce vasoconstriction and inhibit pro-inflammatory neuropeptide release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
standard IV treatment for headache TARGET	standard IV treatment for headache	HCA Florida North Florida Hospital	phase 3	Triptan	5-HT1B, 5-HT1D
Sumatriptan+Promethazine (SPr)	Sumatriptan+Promethazine (SPr)	Shahid Beheshti University of Medical Sciences	phase 3	Serotonin receptor agonist, Antihistamine, Anticholinergic	5-HT1B, 5-HT1D
ALMOTRIPTAN MALATE	ALMOTRIPTAN MALATE		marketed	Triptan	5-HT1B/1D receptors	2001-01-01
Sumatriptan and Naproxen sodium	Sumatriptan and Naproxen sodium	POZEN	marketed	Triptan/NSAID combination	5-HT1B/1D receptors (sumatriptan); COX-1/COX-2 (naproxen sodium)
Imitrex®	Imitrex®	Teva Pharmaceuticals USA	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B and 5-HT1D receptors
conventional migraine drug treatment	conventional migraine drug treatment	Birjand University of Medical Sciences	marketed	Triptan, ergot alkaloid, or NSAID (class varies by specific agent)	5-HT1B/1D receptors (triptans); COX inhibition (NSAIDs); or alpha-adrenergic/serotonergic receptors (ergots)
Sumatriptan Succinate Oral Tablet	Sumatriptan Succinate Oral Tablet	Damanhour Teaching Hospital	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triptan class)

· 1 drug in this class
Assistance Publique Hopitaux De Marseille · 1 drug in this class
HCA Florida North Florida Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). standard IV treatment for headache — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-iv-treatment-for-headache. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab